Literature DB >> 33610185

Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.

Juan de Los Santos-Jiménez1, José A Campos-Sandoval1, Clara Márquez-Torres1, Nieves Urbano-Polo1, David Brøndegaard1, Mercedes Martín-Rufián1, Carolina Lobo1, Ana Peñalver1, María C Gómez-García1, Janet Martín-Campos1, Carolina Cardona1, Laura Castilla1, Felipe da Costa Souza2, Tzuling Cheng3, Juan A Segura1, Francisco J Alonso1, Rui Curi4, Alison Colquhoun2, Ralph J DeBerardinis5,6,7, Javier Márquez1, José M Matés8.   

Abstract

BACKGROUND: Glutaminase isoenzymes GLS and GLS2 play apparently opposing roles in cancer: GLS acts as an oncoprotein, while GLS2 (GAB isoform) has context specific tumour suppressive activity. Some microRNAs (miRNAs) have been implicated in progression of tumours, including gliomas. The aim was to investigate the effect of GLS and GAB expression on both miRNAs and oxidative status in glioblastoma cells.
METHODS: Microarray profiling of miRNA was performed in GLS-silenced LN229 and GAB-transfected T98G human glioblastoma cells and their wild-type counterparts. Results were validated by real-time quantitative RT-PCR. Oxidative status and antioxidant enzymes were determined by spectrophotometric or fluorescence assays in GLS-silenced LN229 and T98G, and GAB-transfected LN229 and T98G.
RESULTS: MiRNA-146a-5p, miRNA-140-3p, miRNA-21-5p, miRNA-1260a, and miRNA-92a-3p were downregulated, and miRNA-1246 was upregulated when GLS was knocked down. MiRNA-140-3p, miRNA-1246, miRNA-1260a, miRNA-21-5p, and miRNA-146a-5p were upregulated when GAB was overexpressed. Oxidative status (lipid peroxidation, protein carbonylation, total antioxidant capacity, and glutathione levels), as well as antioxidant enzymes (catalase, superoxide dismutase, and glutathione reductase) of silenced GLS glioblastoma cells and overexpressed GAB glioblastoma cells significantly changed versus their respective control glioblastoma cells. MiRNA-1246, miRNA-1260a, miRNA-146a-5p, and miRNA-21-5p have been characterized as strong biomarkers of glioblastoma proliferation linked to both GLS silencing and GAB overexpression. Total glutathione is a reliable biomarker of glioblastoma oxidative status steadily associated to both GLS silencing and GAB overexpression.
CONCLUSIONS: Glutaminase isoenzymes are related to the expression of some miRNAs and may contribute to either tumour progression or suppression through certain miRNA-mediated pathways, proving to be a key tool to switch cancer proliferation and redox status leading to a less malignant phenotype. Accordingly, GLS and GAB expression are especially involved in glutathione-dependent antioxidant defence.

Entities:  

Keywords:  Antioxidant enzymes; Cancer; Glioblastoma; Glutaminase; Oxidative stress; microRNA

Year:  2021        PMID: 33610185     DOI: 10.1186/s12929-021-00712-y

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  73 in total

1.  MicroRNA-200c exacerbates the ischemia/reperfusion injury of heart through targeting the glutaminase (GLS)-mediated glutamine metabolism.

Authors:  F Liu; Y Li; G Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-07       Impact factor: 3.507

Review 2.  New insights into brain glutaminases: beyond their role on glutamatergic transmission.

Authors:  Javier Márquez; Marta Tosina; Vanessa de la Rosa; Juan A Segura; Francisco J Alonso; José M Matés; José A Campos-Sandoval
Journal:  Neurochem Int       Date:  2009-03-09       Impact factor: 3.921

3.  Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.

Authors:  Sawako Suzuki; Tomoaki Tanaka; Masha V Poyurovsky; Hidekazu Nagano; Takafumi Mayama; Shuichi Ohkubo; Maria Lokshin; Hiroyuki Hosokawa; Toshinori Nakayama; Yutaka Suzuki; Sumio Sugano; Eiichi Sato; Toshitaka Nagao; Koutaro Yokote; Ichiro Tatsuno; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

4.  Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.

Authors:  Hui-Jin Li; Xu Li; Huan Pang; Jing-Jing Pan; Xiao-Juan Xie; Wei Chen
Journal:  Jpn J Clin Oncol       Date:  2015-09-14       Impact factor: 3.019

5.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.

Authors:  Wenwei Hu; Cen Zhang; Rui Wu; Yvonne Sun; Arnold Levine; Zhaohui Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

6.  Pyruvate carboxylase is required for glutamine-independent growth of tumor cells.

Authors:  Tzuling Cheng; Jessica Sudderth; Chendong Yang; Andrew R Mullen; Eunsook S Jin; José M Matés; Ralph J DeBerardinis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

7.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

Review 8.  MicroRNAs as Multifaceted Players in Glioblastoma Multiforme.

Authors:  Neri Mercatelli; Silvia Galardi; Silvia Anna Ciafrè
Journal:  Int Rev Cell Mol Biol       Date:  2017-04-21       Impact factor: 6.813

Review 9.  Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways.

Authors:  J Liu; A M Albrecht; X Ni; J Yang; M Li
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

Review 10.  Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Authors:  Dharambir Kashyap; Hardeep Singh Tuli; Vivek Kumar Garg; Neelam Goel; Anupam Bishayee
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

View more
  1 in total

Review 1.  Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond.

Authors:  Abdellatif El Khayari; Najat Bouchmaa; Bouchra Taib; Zhiyun Wei; Ailiang Zeng; Rachid El Fatimy
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.